| Send2Press.com • Today is Sunday, February 12, 2012 | A Member of the Neotrope News Network |  |
|
|
NEWS ARCHIVES : U.S. and World News :
Medical :
Drugs and Pharmaceuticals
News
|
Press Release:
Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate with Additional U.S. Patents
Tumor-targeted Gene Delivery Gains in Medicine and Patent Protection.SAN MARINO, Calif., July 6 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances covering tumor-targeted gene delivery and precision-targeted cancer immunotherapy, respectively. Like the exceedingly tiny, precision targeted, stealthy tumor-seeking nanomedicine itself, this small California biotechnology company has advanced to the forefront of the biopharmaceutical "War on Cancer" with formal demonstrations of safety and efficacy in the clinic and best-of-breed solutions for the pharmaceutical industry. As the development of its lead oncology product advances in the clinic towards regulatory approval, the critical proofs-of-principle, i.e., definitive demonstrations of overall safety and single-agent efficacy in clinical trials, serve as the scientific and innovative basis for attaining additional patent protections in the emerging field of tumor-targeted biologics. Indeed, Epeius Biotechnologies has accumulated more than 150 issued/allowed/granted patents in the area of genetic medicine, including more than 40 pending applications. Furthermore, the U.S. FDA has recently granted Orphan Drug status to Rexin-G, the company's lead product, for three separate clinical indications based on formal evaluations of clinical safety and potential efficacy, which provides additional market protections and economic incentives pertaining to such a significant and yet unmet medical need as the treatment of chemotherapy-resistant cancers. Exhibiting broad-spectrum anti-cancer activity against many otherwise intractable cancers, Rexin-G has demonstrated a number of first-in-class, best-in-class characteristics: (1) The tumor-targeting properties of the gene delivery platform are profound, capable of seeking-out, accumulating-in, and halting-the-progression-of widespread cancers by means of simple intravenous infusions. (2) The broad-spectrum anti-cancer activity is achieved "by design," as the genetic payload is focused on a critical locus of cellular growth control and tumor suppression. (3) Years of progressive clinical trials have advanced the field by establishing cumulative safety (with no dose-limiting toxicities), practical pharmacological thresholds, quantitative dose-response relationships, and clinical infusion protocols which optimize patient benefits, including significant survival benefits. (4) Equally important are the advancements in biopharmaceutical science that provide for greater purities, potencies, GMP productivity, and economies-of-scale, and which translate into more-affordable treatments for cancer patients. All in all, it seems that Small, Smart, and Stealth may turn out to be a very cool hand to grasp, and to hold on to. About Epeius Biotechnologies: Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems. Rexin-G® is currently approved for the treatment of all chemotherapy-resistant solid tumors by the Philippine FDA. To learn more about our lead products and/or our pipeline of proprietary biotechnologies, please visit us at www.epeiusbiotech.com. For recent papers, expert reviews, clinical reports in oncology and molecular therapy, etc., see the "Publications" section on our website.
NEWS SOURCE: Epeius Biotechnologies Corporation
Send2Press® is the originating wire service for this story. Terms of Use. © Epeius Biotechnologies Corporation. All trademarks acknowledged.
THE CONTENT OF THE ABOVE PRESS RELEASE WAS PROVIDED BY THE NEWS SOURCE (Epeius Biotechnologies Corporation), WHO IS SOLELY RESPONSIBLE FOR ITS ACCURACY. FOR QUESTIONS ABOUT THIS STORY CONTACT THE NEWS SOURCE AND NOT THIS WEBSITE.
Journalist Resources:
Download original press release as issued including media contact information for Epeius Biotechnologies Corporation.
Additional News Releases on Similar Topics:
|
Subscribe to Send2Press®
Daily News Releases by E-Mail
Follow Send2Press on Social Sites: 
Additional News from
Epeius Biotechnologies Corporation : » Epeius Biotechnologies Awarded Federal Grant Advancing Tumor-Targeted Cancer Therapy
|
||||||||||||||||||||||||||
View our news channels by industry topics, by U.S. States, or by selected U.S. Cities:
|
Terms of Use and License
This "article format" version of the issued press release is Copr. © 1983-2012 Neotrope/Send2Press. You may freely link to this article version of the press release or may use the release text as the basis for an original article or news posting. If the content is copied verbatim via a scraping or copy/paste method, the news item must be properly "attributed" to Send2Press® Newswire as the originating wire service for this story (may not be posted on ANY site selling/offering SEO or PR services, newswire services, or adult content!). |
DISCLAIMER: the above press release content is believed accurate but not guaranteed, and is based on business news supplied by the source. The noted source is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements. Neotrope/Send2Press (this website) makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news and profiles are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope® or Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. All trademarks acknowledged.
REFERENCES: Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate with Additional U.S. Patents, targeted genetic medicine, Epeius Biotechnologies Corporation, tumor-targeted gene delivery platform, Rexin-G, tumor-seeking nanomedicine, metastatic disease, Orphan Drug status, biologics, broad-spectrum anti-cancer activity, treatment of chemotherapy-resistant cancers, press release, Jul 6, 2010. |
|
THIS PAGE MEDIA READS (by media and public, as of today): 2257 times (2 today, 2 this week, 20 this month, 48 this year)
Site Design and Content is Copr. © 1983 - 2011 Neotrope® - All rights reserved. Send2Press® is a reg. trademark and service mark of NEOTROPE.
Press Release Writing | About Send2Press | Meet Our Staff | Contact Us | Our Services | Help Desk | Legal | Privacy | How-To Articles | RSS Feeds | Journalist Tools | Client eMediaKits | Headline Feeds | Podcast | PR News Channels | Daily News Desk | Success Stories | PRTRax™ Reader Tracking | Targeted News Distribution | Internet Marketing Services | Order PR Services | Terms of Service (TOS)